Skip NavigationSkip to Content

Wilms' tumorigenesis is altered by misexpression of the transcriptional co-activator, CITED1

  1. Author:
    Lovvorn, H. N.
    Boyle, S.
    Shi, G.
    Shyr, Y.
    Wills, M. L.
    Perantoni, A. O.
    de Caestecker, M.
  2. Author Address

    Vanderbilt Univ, Childrens Hosp, Dept Pediat Surg, Sch Med, Nashville, TN 37232 USA. Vanderbilt Univ, Sch Med, Div Nephrol, Nashville, TN 37232 USA. Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA. Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37232 USA. Vanderbilt Univ, Sch Med, Dept Pediat Pathol, Nashville, TN 37232 USA. NCI, Lab Comparat Carcinogenesis, Ft Detrick, MD 21702 USA.;Lovvorn, HN, Vanderbilt Univ, Childrens Hosp, Dept Pediat Surg, Sch Med, 221 Kirkland Hall, Nashville, TN 37232 USA.;harold.lovvorn@vanderbilt.edu
    1. Year: 2007
    2. Date: Mar
  1. Journal: Journal of Pediatric Surgery
    1. 42
    2. 3
    3. Pages: 474-481
  2. Type of Article: Article
  3. ISSN: 0022-3468
  1. Abstract:

    Purpose: Wilms' tumors arise from arrested differentiation of renal progenitor cells. CITED1 is a transcriptional regulator that blocks the metanephric mesenchymal-to-epithelial conversion and is expressed in the blastema of both the developing kidney and Wilms' tumors. We hypothesized that alterations of CITED1-dependent signaling promote persistence of blastema and thereby subject these pluripotent cells to future oncogenic events. Methods: We used a retroviral delivery system to overexpress the full-length CITED I (F/L) protein and 2 deletion mutants lacking either of its known functional domains, Delta SID (Smad-4 Interacting Domain) and Delta CR2 (Conserved Region 2; the CITED1 transactivation domain), in a human Wilms' tumor cell line that endogenously expresses CITED1. In vitro effects on cellular proliferation and apoptosis were assayed. In vivo effects on tumorigenesis, growth, proliferation, and apoptosis were determined after heterotransplantation into immunodeficient mice (n = 15 per cell line). Results: In vitro, overexpression of CITED1-F/L significantly increased, whereas overexpression of the functionally inactivating mutant, CITED1-Delta CR2, significantly reduced cellular proliferation relative to the other lines (P <.0001). In vivo, Wilms' tumor incidence was significantly reduced in animals injected with cells overexpressing the mutant CITED1-Delta CR2 (7%) compared with CITED1-F/L (40%, P=.03) and CITED1-Delta SID (60%, P <.002). Similarly, mean tumor volume was least in the CITED1-Delta CR2 animals when compared with CITED1-F/L (P=.03) and CITED1-Delta SID animals (P <.005). Furthermore, the CITED1-Delta CR2 tumor showed the least cellular proliferation. Misexpression of CITED I did not affect apoptosis either in vitro or in vivo. Conclusions: Overexpression of CITED1 in a human Wilms' tumor cell line significantly increases proliferation in vitro, whereas mutation of its functionally critical transactivation domain (Delta CR2) significantly reduces proliferation. This mutation further perturbs tumorigenesis and tumor growth after heterotransplantation into immunodeficient mice. We speculate that overexpression of CITED1 promotes expansion of a rapidly proliferating population of blastema and thereby induces an unstable environment highly susceptible to future oncogenic events. (c) 2007 Elsevier Inc. All rights reserved.

    See More

External Sources

  1. DOI: 10.1016/j.jpedsurg.2006.10.054
  2. WOS: 000245002900005

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel